Engineers small molecules that force cells to destroy disease-causing proteins that no other drug can touch.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- ScaleMarket cap is above the global median
Engineers small molecules that force cells to destroy disease-causing proteins that no other drug can touch.
What this company is and how it runs — written from structure, not news.
Kymera Therapeutics builds small molecules called PROTACs that destroy disease-causing proteins inside cells by forcing a three-way physical contact between the target protein, the PROTAC, and a naturally occurring enzyme called an E3 ligase — a mechanism that can reach proteins that conventional drugs cannot block. Because that three-way grip cannot be predicted from textbook biology alone, every new target requires screening hundreds of candidate linker designs to find the geometry that actually works, and Kymera records each success and failure as proprietary training data for its computational platform. That dataset is the engine of the whole business: the platform uses it to guess which linker to try next, each campaign makes the guesses more reliable, and a competitor cannot buy or license the same accuracy because it would have to rerun every historical experiment in the original sequence to recreate it. What the platform cannot compress is the clinical side — each new protein target still needs its own human dose-escalation study, its own safety data, and its own biomarker evidence from scratch, so scientific progress on the computational side does not shorten the timeline or cost on the medical side.
How does this company make money?
The company receives upfront cash payments when it licenses a PROTAC program to a pharmaceutical partner. It also receives additional milestone payments as those programs clear development hurdles — such as entering clinical trials or reaching late-stage testing. If a partnered drug is eventually approved and sold, the company earns royalties based on a share of net sales.
What makes this company hard to replace?
A clinical investigator who is already running a trial cannot swap in a competing protein degrader midway through, because a different molecule using a different E3 ligase will have different degradation behavior and will require entirely new biomarker validation before anyone knows if it is working. Regulators also treat each structurally distinct PROTAC as a separate drug: even if two molecules target the same protein, each one needs its own IND filing, meaning the paperwork and review process starts over from the beginning.
What limits this company?
No matter how good the prediction platform gets, every single new disease target still has to be tested in the lab to confirm that the three-way molecular grip actually forms. A correct computational guess does not skip that step. Because that confirmation work cannot be inherited from any prior program, each new target costs roughly the same amount of experimental time as the last one.
What does this company depend on?
The company cannot operate without access to VHL and CRBN ligands, which are the chemical handles used to recruit E3 ligase enzymes into the three-way complex. It relies on contract research organizations to synthesize and optimize PROTAC molecules in the lab. Running clinical trials requires FDA Investigational New Drug applications for each program, clinical trial sites equipped to monitor patient biomarkers, and specialized laboratory methods capable of measuring whether the target protein is actually being destroyed inside patients.
Who depends on this company?
Patients with IRAK4-driven blood cancers depend on the company's targeted degrader therapy — if it stopped, no equivalent treatment exists. Patients enrolled in STAT3 degrader trials for autoimmune diseases would have to fall back on broad-acting immunosuppressive drugs rather than a treatment aimed at the specific protein driving their disease. Academic researchers studying how cells degrade proteins also rely on the company's proprietary PROTAC compounds to run their experiments.
How does this company scale?
The computational platform and target-identification algorithms get more useful as more data accumulates, and applying them to a new protein target costs relatively little once the system is running. What does not get cheaper is the clinical side: every new protein target still needs its own dose-escalation study, its own safety data, and its own set of biomarkers developed from scratch — and none of that work is shortened by having already done it for a different target.
What external forces can significantly affect this company?
Medicare and Medicaid reimbursement decisions will shape whether approved PROTAC therapies can actually be sold at prices that make development worthwhile. The European Medicines Agency and FDA have not yet fully aligned on what biomarker evidence is required to approve a protein degradation drug, which creates regulatory uncertainty across markets. China's separate approval framework for first-in-class protein degraders adds another layer of complexity that could slow or complicate global development timelines.
Where is this company structurally vulnerable?
The platform's value is not just in the data — it is in the specific way the data was labeled and structured, and in how the models were built on top of it. If the people who designed those schemas and built that architecture left the company, the raw experimental records would still exist but no one would be able to interpret them correctly or extend the models to new targets. The dataset would persist; the ability to use it productively would not.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations have aligned in the up direction: the Ichimoku-cloud composite is firing on its up-side configuration, the trend-strength composite is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph